Shili Xu, PhD

Shili Xu, PhD

Assistant Professor, Department of Molecular and Medical Pharmacology
Director, Preclinical Imaging, Crump Institute for Molecular Imaging
Member, JCCC Community



Contact Information

Scientific Interests

Dr. Shili Xu is interested in the development of in vivo state-of-the-art molecular imaging technologies, including positron emission tomography (PET), computed tomography (CT) and optical (fluorescence and bioluminescence) imaging. He applies these technologies for non-invasive assessment of cancer, immune response, neurological disorders, cardiology and associated biology, as well as preclinical probe and drug development in small animal models. Specifically, his team has developed a broad spectrum of PET probes and reporter genes to preclinically image cell metabolism, monitor cell trafficking and activation and profile drug pharmacokinetic/pharmacodynamics and tracer kinetics.

Highlighted Publications

Xu S, Herschman HR. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers. Cancer Res. 2019 Dec 1;79(23):5907-5914. doi: 10.1158/0008-5472.CAN-19-1789. Epub 2019 Aug 21. Review.

Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, MacLeod AR, Morrison SL, Herschman HR. An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma. Cancer Res. 2019 May 15;79(10):2748-2760. doi: 10.1158/0008-5472.CAN-18-2799. Epub 2019 Mar 18.

Elliott IA, Dann AM, Xu S, Kim SS, Abt ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, Cabebe AE, Wu N, Li L, Le TM, Radu CG, Donahue TR. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proc Natl Acad Sci U S A. 2019 Apr 2;116(14):6842-6847. doi: 10.1073/pnas.1812410116. Epub 2019 Mar 20.

Xu S, Catapang A, Doh HM, Bayley NA, Lee JT, Braas D, Graeber TG, Herschman HR. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin. J Nucl Med. 2018 Jun 7. pii: jnumed.118.212365. doi: 10.2967/jnumed.118.212365. [Epub ahead of print]

Xu S, Catapang A, Braas D, Stiles L, Doh HM, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. Cancer Metab. 2018 Jun 28;6:7. doi: 10.1186/s40170-018-0181-8. eCollection 2018.